World Orphan Drugs Market Explored by Kalorama Information in In-demand Report Available at MarketPublishers.com
09 Jul 2013 • by Natalie Aster
LONDON – There has been a considerable increase in the number of drugs available to treat rare, or so called ‘orphan’, diseases recently. Drugs and biological products to treat these conditions are typically referred to as ‘orphan drugs’. Cancer is a major opportunity for biotech companies as return on investment could often turn positive. Infectious diseases highlight the pressing need for new therapies with novel mechanisms of action to avoid growing issues affecting this industry including a top area of concern — drug resistance.
The increasing incidence of diseases affecting older people is expected to drive the world orphan drug market from a value of 61bn in 2012 to over USD 105bn by end-2017. In the US, the largest country-level market, adequate initiatives to treat many rare diseases have been taken, thus creating a thriving marketplace for orphan drug treatments. Amgen, Novartis and Roche are likely to be the world’s leading market contributors.
In-demand report “The World Market for Orphan Drugs” worked out by Kalorama Information presents an up-close look at the various trends and factors affecting, and are expected to affect the orphan drugs market in the United States, Europe, Japan and globally from 2012 through to 2017.
The study thoroughly examines what pharmaceutical giants and smaller firms are doing within this drug category. It features company market share for both the US and global markets. In-depth coverage of a variety of competitors with designations and designation/approvals alike, as well as major trends and challenges for makers of orphan drug treatments is provided in the research.
The World Market for Orphan Drugs
Published: June, 2013
Price: US$ 4,500.00
More in-demand reports by the publisher can be found at Kalorama Information page.